Natco Pharma, Dr. Reddy’s file Doxorubicin Hydrochloride Liposome Injection in Europe

13 Aug 2018 Evaluate

Natco Pharma and its co-development and marketing partner Dr. Reddy’s Laboratories have filed for Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil, for intravenous use, for the European Markets.

Janssen’s brand Doxil is predominantly used for the treatment of metastatic breast cancer, advanced ovarian cancer and progressive multiple myeloma. The Doxil brand, 2mg/ml, had sales of around $130.5 million, in Europe, for the 12 months ending December 31, 2017, according to Quintiles IMS.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.


Natco Pharma Share Price

909.10 15.75 (1.76%)
05-Jan-2026 14:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1735.20
Dr. Reddys Lab 1251.30
Cipla 1521.05
Zydus Lifesciences 922.70
Lupin 2085.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×